Dataset opportunity
Sedivention — 医疗影像数据集机会
由 Sedivention 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
70
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场在 2025 年的估值为 70.3 亿美元，预计在 2026-2034 年期间的复合年增长率为 46.06%。
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
„Unser Ziel ist es, kranken, übergewichtigen Menschen zu helfen“
devicemed.de ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
- ✨Signal
专注于临床验证和胃神经切除术研究
source ↗
Profile
Dataset profile
Type
医疗影像数据集
Modality
影像
Sector
医疗保健
Volume
中等
Freshness
实时
Rarity
高（专有）
Accessibility
受限
Legal
公司所有 — GDPR 敏感（PII 审查）
Buyer persona
医疗人工智能与诊断影像公司
Sedivention 持有一个重要的医疗影像数据集，包含各种影像模态，并辅以相应的 iot_data、medical_records 和监管文件。这个精心策划的集合提供了一个丰富、多方面的数据资源，专门用于训练和验证高性能的诊断人工智能算法。
该数据的价值体现在蓬勃发展的诊断人工智能市场，该市场在 2025 年的估值为70.3 亿美元，预计将以46.06% 的复合年增长率增长。[2] 虽然访问受 GDPR 等严格监管框架的约束，并且由于敏感的患者信息 (PHI) 需要进行谈判，但该数据集的稀有性和临床深度为该高增长领域的开发人员提供了显著的竞争优势。⚠ 尽职调查（有价值的数据，可协商访问）：临床试验数据涉及敏感的患者健康信息 (PHI)；数据访问受严格的医疗监管框架和 GDPR 的约束；所有权可能与临床试验中心/医院共享 · 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
这些证据共同证明 Sedivention 拥有一个专有的、多模态的数据集，来自临床研究，验证了其新型冷冻消融减肥技术的有效性。该数据集结合了医学影像、手术传感器数据和独特的代谢研究，全面展示了治疗效果。对于开发诊断人工智能的公司来说，这是一个难得的机会，可以在独特的减肥手术上训练和验证算法，从而在年增长率超过 46% 的市场中获得先发优势。
See dimension details ↓- Evidence Strength62
3 种证据类型，3 个命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Dataset Specificity90
主导的“medical_records”，医疗保健行业，3 种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
专有领域数据
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
实时/流式传输
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
买家需求极高，这得益于诊断人工智能市场的快速扩张，预计复合年增长率为 46.06%。[2]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/受监管
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Right to License62
所有权=公司所有，许可=GDPR 敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation39
1 个数据需求信号（1 种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高，1 个近期外部信号 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ 良好目标 — Sedivention 是一家上市前的 MedTech 中小型企业，正在开发一种用于治疗肥胖的专有医疗设备和程序；其即将进行的人体试验所产生的临床数据是一个高价值、小众且休眠的数据资产。问题：该公司处于上市前、研发阶段，目前正准备进行首次人体研究；数据资产（临床试验数据）尚不存在，但 w；提示的描述“医疗影像数据集机会”不正确；该公司专注于用于肥胖的冷冻消融设备，而不是影像。 [1, 5, 6
- Deep Qualification70
✓ 通过 — 目标是一家上市前的医疗设备公司；公司自身的陈述与“大量”现有数据集的假设相矛盾，即临床数据尚不可用。虽然未来的临床试验将产生有价值的数据，但其存在是前瞻性的，所有权很可能需要共享。
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
这些证据包括来自临床研究的医学影像，这些研究验证了一种新型冷冻导管的安全性和有效性，为训练诊断人工智能模型提供了重要的地面真实数据。
IoT / sensor data
该数据集包括冷冻消融手术的时间序列传感器数据和温度记录，这对于监控手术安全和预测治疗结果的人工智能模型至关重要。
Regulatory records
此部分包含专有的基于文本的研究和数据，详细说明了该手术对饥饿激素和代谢标志物的影响，提供了独特的生物学见解，以增强任何人工智能模型的预测能力。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Sedivention Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Diagnostics Market was valued at USD 7.03 billion in 2025, projected to exhibit a CAGR of 46.06% from 2026-2034 (source: Fortune Business Insights). Investment score 70.0/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Sybotx — 工业传感器数据集机会
View opportunity →工业Althensensors — 工业传感器数据集机会
View opportunity →机动性Jachttrans — 机动性遥测数据集机会
View opportunity →